Transcode Therapeutics Inc
Change company Symbol lookup
Select an option...
RNAZ Transcode Therapeutics Inc
JLL Jones Lang LaSalle Inc
FGEN FibroGen Inc
ETR Entergy Corp
ACMR ACM Research Inc
RGAGX American Funds The Growth Fund of America® Class R-6
ATRC AtriCure Inc
CTRA Coterra Energy Inc
CINF Cincinnati Financial Corp
ATOM Atomera Inc
Go

Health Care : Biotechnology |
Company profile

TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company’s development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b. The Company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B. Its TTX platform is modular by design, both at the level of the core nanoparticle and at the therapeutic loading.

Postmarket

Last Trade
Delayed
$1.33
0.09 (7.26%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.24
Day's Change
-0.02 (-1.59%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.26
Day's Low
1.24
Volume
(Light)
Volume:
1,841

10-day average volume:
56,738
1,841

Display:

Providers:

UpdateCancel
6 providers
June 09, 2022
TransCode Therapeutics to Participate at BIO International Convention

EQNX::TICKER_START (NASDAQ:RNAZ), EQNX::TICKER_END TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue...(Globe Newswire)

June 01, 2022
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

EQNX::TICKER_START (NASDAQ:RNAZ), EQNX::TICKER_END Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors (Globe Newswire)

May 20, 2022
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

EQNX::TICKER_START (NASDAQ:RNAZ), EQNX::TICKER_END TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the...(Globe Newswire)

May 19, 2022
TransCode Therapeutics Acquires Option for Radiotheranostic Technology

EQNX::TICKER_START (NASDAQ:RNAZ), EQNX::TICKER_END TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving...(Globe Newswire)

May 16, 2022
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update

EQNX::TICKER_START (NASDAQ:RNAZ), EQNX::TICKER_END TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31...(Globe Newswire)

April 13, 2022
TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its Co-Founder and Chief Technology Officer, Dr. Zdravka Medarova, will moderate the 7 Annual...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.